» Articles » PMID: 33908781

Targeting the FtsZ Allosteric Binding Site with a Novel Fluorescence Polarization Screen, Cytological and Structural Approaches for Antibacterial Discovery

Abstract

Bacterial resistance to antibiotics makes previously manageable infections again disabling and lethal, highlighting the need for new antibacterial strategies. In this regard, inhibition of the bacterial division process by targeting key protein FtsZ has been recognized as an attractive approach for discovering new antibiotics. Binding of small molecules to the cleft between the N-terminal guanosine triphosphate (GTP)-binding and the C-terminal subdomains allosterically impairs the FtsZ function, eventually inhibiting bacterial division. Nonetheless, the lack of appropriate chemical tools to develop a binding screen against this site has hampered the discovery of FtsZ antibacterial inhibitors. Herein, we describe the first competitive binding assay to identify FtsZ allosteric ligands interacting with the interdomain cleft, based on the use of specific high-affinity fluorescent probes. This novel assay, together with phenotypic profiling and X-ray crystallographic insights, enables the identification and characterization of FtsZ inhibitors of bacterial division aiming at the discovery of more effective antibacterials.

Citing Articles

Computational docking of FtsZ: Survey of promising antibiotic compounds.

Espino I, Drolet J, Jones T, Uwechue A, Koehler B, Beaird R Biochem Biophys Rep. 2024; 39:101796.

PMID: 39687410 PMC: 11647940. DOI: 10.1016/j.bbrep.2024.101796.


Molecular dynamics simulations reveal differences in the conformational stability of FtsZs derived from Staphylococcus aureus and Bacillus subtilis.

Takasawa T, Matsui T, Watanabe G, Kodera Y Sci Rep. 2024; 14(1):16043.

PMID: 38992051 PMC: 11239868. DOI: 10.1038/s41598-024-66763-x.


Filamentous temperature sensitive mutant Z: a putative target to combat antibacterial resistance.

Kifayat S, Yele V, Ashames A, Sigalapalli D, Bhandare R, Shaik A RSC Adv. 2023; 13(17):11368-11384.

PMID: 37057268 PMC: 10089256. DOI: 10.1039/d3ra00013c.


Homology modeling, virtual screening, molecular docking, and dynamics studies for discovering FtsZ inhibitors.

Vemula D, Maddi D, Bhandari V Front Mol Biosci. 2023; 10:1087676.

PMID: 36936991 PMC: 10020519. DOI: 10.3389/fmolb.2023.1087676.


Importance of the 2,6-Difluorobenzamide Motif for FtsZ Allosteric Inhibition: Insights from Conformational Analysis, Molecular Docking and Structural Modifications.

Barbier T, Dumitrescu O, Lina G, Queneau Y, Soulere L Molecules. 2023; 28(5).

PMID: 36903302 PMC: 10003973. DOI: 10.3390/molecules28052055.


References
1.
Marin-Ramos N, Balabasquer M, Ortega-Nogales F, Torrecillas I, Gil-Ordonez A, Marcos-Ramiro B . A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia. J Med Chem. 2019; 62(13):6035-6046. DOI: 10.1021/acs.jmedchem.9b00145. View

2.
Bi E, Lutkenhaus J . FtsZ ring structure associated with division in Escherichia coli. Nature. 1991; 354(6349):161-4. DOI: 10.1038/354161a0. View

3.
Chai W, Whittall J, Song D, Polyak S, Ogunniyi A, Wang Y . Antimicrobial Action and Reversal of Resistance in MRSA by Difluorobenzamide Derivatives Targeted at FtsZ. Antibiotics (Basel). 2020; 9(12). PMC: 7762090. DOI: 10.3390/antibiotics9120873. View

4.
Artola M, Ruiz-Avila L, Vergonos A, Huecas S, Araujo-Bazan L, Martin-Fontecha M . Effective GTP-replacing FtsZ inhibitors and antibacterial mechanism of action. ACS Chem Biol. 2014; 10(3):834-43. DOI: 10.1021/cb500974d. View

5.
Haydon D, Stokes N, Ure R, Galbraith G, Bennett J, Brown D . An inhibitor of FtsZ with potent and selective anti-staphylococcal activity. Science. 2008; 321(5896):1673-5. DOI: 10.1126/science.1159961. View